Speaker Programs and Congresses Can Be Data-Driven Too

Posted by Ankita Praharaj on Mon, Feb 03, 2020

Kumail Fazal co-wrote this blog post with Ankita Praharaj 

Speaker programs and congresses are a key component of the promotional mix strategy for pharmaceutical companies and are used to educate HCPs about the latest products, product benefits, and the best ways to use them. Every year, organizations set aside considerable funds for executing speaker programs and congresses.


>
Read More

Ramping Up Real-World Evidence: Assessing the FDA’s New RWE Framework

Posted by Qin Ye on Thu, Jan 24, 2019

Ishita Srivastava and Divya Babbar co-authored this blog post with Qin Ye.

The FDA considers the use of real-world data and real-world evidence a top strategic priority, and on Dec. 6, it unveiled its much-anticipated RWE framework to support the development of drugs and biologics. The framework is aimed at evaluating the potential use of RWE for assessing a product’s effectiveness and focuses on increased stakeholder engagement to effectively leverage RWD and RWE for public health purposes.


>
Read More

Pharma Should Be Making More Data-Driven Deployment Decisions

Posted by Pratap Khedkar on Wed, Nov 28, 2018

This is the second post in a three-part series on commercial resource planning.

As the pharma industry’s customers evolve with the shifts in the healthcare landscape, pharma companies can no longer take a static, semiannual, one-size-fits-all approach to commercial resource planning. They need to take an agile, localized, customized approach to aligning commercial resources to better meet their customers’ evolving needs—and they need the right analytics capability to mine the customer and market insights they need to get it done.


>
Read More